Filgotinib Maleate

Galapagos’ name change to Lakefront Biotherapeutics approved at the Company’s EGM (Euronext & NASDAQ: LKFT) Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026 Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation priorities Year-end 2026 cash and financial investments balance expected to be approximately €2B Management to host conference call on May 7, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium ; May 6, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the first quarter of 2026 and provided a business update. “Having joined the company just one year ago, I’m thrilled with our progress. I am looking forward to consummating our partnership with Gilead and adding Ouro Medicines’ talented team and its portfolio of programs to our Company, including the potential first and best in class T cell engager in autoimmune diseases, gamgertamig (OM336). We are excited that our Company is rebranding as Lakefront Biotherapeutics as this name reflects our Company’s strategic evolution,” said Henry Gosebruch, Chief Executive Officer of Galapagos. Aaron Cox, Chief Financial Officer of Galapagos, added, “Following the anticipated use of cash to fund our collaboration with Gilead concerning its acquisition of Ouro Medicines, the Company will remain robustly capitalized and will have increased flexibility, including the ability to spend up to $500 million for business development independent of Gilead and not subject to our 2019 Option, License, and Collaboration Agreement with Gilead. This would also include the potential to use up to $150 million of that $500 million for share repurchases to the extent that we have available distributable reserves. In addition to the upfront consideration of $837.5 million, we anticipate additional 2026 Ouro-related cash expenditures to be in the range of €60-75 million, inclusive of R&D costs, one-time transaction costs and assuming a mid-year closing of the transaction.” First Quarter 2026 Business Update On March 31, 2026, the Company announced that it has entered into a binding agreement (the “Framework Agreement”) with Gilead Sciences, Inc. (“Gilead”) (the “Transaction”) in connection with Gilead’s definitive agreement to acquire all of the outstanding equity interests of US-based Ouro Medicines, LLC (“Ouro”), a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. Gamgertamig (OM336) is a clinical stage BCMAxCD3 T cell engager designed to enable rapid and deep plasma and B cell depletion following a short duration, subcutaneously administered treatment course. In ongoing Phase 1/2 clinical studies, gamgertamig has demonstrated transformative efficacy and a differentiated safety pro a single treatment cycle in severe antibody-mediated orphan diseases, including autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Gamgertamig has been granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of AIHA and ITP and is expected to enter registrational studies as early as 2027. BCMA-targeted T cell engagers are being investigated as a precision approach for severe inflammatory and autoimmune diseases by eliminating pathogenic B cells and plasma cells. By redirecting a patient’s own T cells toward BCMA-expressing plasma cells, clinical data suggest these agents can reduce inflammation, improve organ-level disease, and in some cases enable durable, drug-free remission without ongoing immunosuppression. Update on Binding Agreement with Gilead The Company expects the Transaction to close in the second quarter of 2026, subject to the fulfillment of the closing conditions. Galapagos expects to assume substantially all of Ouro’s operating assets and personnel (approximately 20 employees), such that the Company would obtain an operating business. Galapagos and Gilead will equally split the upfront payment of $1.675 billion (~€1.425 billion 1 ), subject to customary adjustments, and contingent milestone payments of up to $500 million (~€425 million 1 ). Galapagos and Gilead will collaborate on the development of gamgertamig, with Galapagos responsible for the development costs through initiation of registrational studies, after which the development costs will be shared equally. Galapagos is eligible for up to $100 million in development milestones payments for gamgertamig in certain other indications. Galapagos will fund its share of payments owed to KeyMed Biosciences Chengdu Co., Ltd. (“KeyMed”), comprising 25% of the milestone payments and 50% of the royalty payments that become due to KeyMed with respect to gamgertamig products. Based on Ouro’s original transaction with Keymed, Keymed is entitled to total development and commercial milestones of up to $610 million and tiered royalties of 7%-14% of net sales for gamgertamig. Gilead will retain sole worldwide commercialization rights, including all related costs, globally outside of Keymed’s territories, and Galapagos will receive tiered royalties of 20%–23% on net sales of gamgertamig from Gilead. Galapagos will gain a preclinical portfolio of three additional autoimmune focused programs originally from Ouro, with an opt-in for Gilead for a 50/50 profit split post clinical proof-of-concept for $75 million (~€64 million 1 ) per program. The proposed arrangements will amend the existing collaboration terms with Gilead to designate $500 million (~€425 million 1 ) of Galapagos’ cash available for R&D or strategic transactions outside of Gilead partnerships, including up to $150 million (~€128 million 1 ) of this $500 million (~€425 million 1 ) for potential return of capital, subject to certain limitations. In addition to the upfront payment of $837.5 million (~€713 million 1 ), the range of spending expected (including transaction expenses, operating expenses, milestones, and royalties) in 2026 is €60-€75 million. Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash of approximately €3B remaining for additional strategic transactions and other capital allocation priorities. 1 Converted at a rate €/$ 1.175, consistent with year-end 2025 CORPORATE At the Company’s Annual and Extraordinary Shareholders’ Meeting held on April 28, 2026 (the “AGM” and “EGM”) all proposed resolutions were approved (see: press release of April 28, 2026 ), among other items: the name change to Lakefront Biotherapeutics, with effect as of May 8, 2026. Our ticker on Euronext and NASDAQ (ADRs) will change to LKFT; Gino Santini’s appointment as a member of our Board of Directors, and pursuant to a vote of our Board of Directors, Gino became the new Chair of our Board of Directors. Gino replaces Jérôme Contamine, whose four-year mandate as a member of the Board of Directors ended upon the conclusions of the AGM; the authorization to acquire the Company’s own shares. In April 2026, Coultreon Biopharma BV (“Coultreon”), previously named Onco3R Therapeutics BV, announced the closing of an oversubscribed $125 million Series A financing round. The financing will support the clinical development of Coultreon’s lead immunology program, COL-5671 (formerly O3R-5671), a highly selective SIK3 inhibitor in Phase 1, with potential to demonstrate clinical proof-of-concept in 2027. COL-5671 was initially developed by Galapagos and ownership was fully transferred to Coultreon in April 2025, when Galapagos provided seed financing to the company with a convertible note investment that converted into equity ownership in Coultreon in connection with Series A financing. IMMUNOLOGY SMALL MOLECULE PIPELINE As part of our ongoing efforts to maximize the value of the GLPG3667 program for both patients and Galapagos, we are evaluating all strategic options. The GALACELA SLE study with GLPG3667 is currently ongoing, and the final Week 48 data are expected in the second quarter of 2026. ONCOLOGY CAR-T CELL THERAPY UPDATE The Company announced in January 2026 the start of the wind-down of its cell therapy activities. The wind-down remains on schedule and is expected to be substantially completed by the end of the third quarter of 2026. The Company continues to expect 2026 one-time cash costs related to the wind-down to be in the range of €125 million to €175 million. Financial Guidance Galapagos currently estimates 2026 cash spend related to Ouro of approximately €775 million to €790 million, inclusive of the upfront payment, transaction costs, and operating costs assuming a mid-year transaction closing. The Company expects its year end 2026 cash and financial investments balance to be in the range of €1.975 billion to €2.050 billion, which reflects a reduction in prior guidance due to expected cash usage related to the Ouro investment and a corresponding reduction in interest income. Galapagos continues to expect one-time cash restructuring costs of €125 million to €175 million related to the ongoing wind-down of the cell therapy activities. All figures assume a EUR/USD exchange rate of 1.175, consistent with year-end 2025. These estimates are subject to change and depend on the timing of closing, final transaction scope, integration activities, exchange rate fluctuations, and remaining cell therapy wind-down costs. Financial Performance Key figures for the first quarter of 2026 (consolidated) (€ millions, except basic & diluted earnings/loss (-) per share) March 31, 2026 March 31, 2025 % Change Supply revenues 4.9 13.8 -64% Collaboration revenues 1.6 61.2 -97% Total net revenues 6.5 75.0 -91% Cost of sales (4.8) (13.8) -65% R&D expenses (31.0) (182.7) -83% G&A 1 and S&M 2 expenses (35.5) (43.8) -19% Other operating income 1.1 6.6 -83% Operating loss (63.7) (158.7) Fair value adjustments and net exch­ange differences 64.3 (9.4) Net other financial result 13.4 11.8 Income taxes (0.1) 1.8 Net profit/loss (-) from continuing operations 13.9 (154.5) Net profit from discontinued operations, net of tax 0.6 1.1 Net profit/loss (-) of the period 14.5 (153.4) Basic and diluted earnings/loss (-) per share (€) 0.2 (2.3) Financial investments, cash & cash equivalents 2,982.2 3,297.3 Details of the financial results for the first quarter of 2026 Total operating loss from continuing operations for the first three months of 2026 amounted to €63.7 million, compared to an operating loss of €158.7 million for the first three months of 2025. The operating loss in 2025 was negatively impacted by the executed strategic reorganization announced in January 2025, for €111.0 million. This was mainly reflected in severance costs of €47.5 million, costs for early termination of collaborations of €42.1 million and impairment on fixed assets related to small molecules activities of €10.2 million, professional services costs of €6.6 million and €4.2 million accelerated non-cash cost recognition for subscription right plans. Total net revenues amounted to €6.5 million for the first three months of 2026, compared to €75.0 million for the first three months of 2025. The revenue recognition related to the exclusive access rights granted to Gilead for Galapagos’ drug discovery platform amounted to €57.6 million for the first three months of 2025. The deferred income related to the drug discovery platform was fully released in revenue at the end of 2025. Cost of sales amounted to €4.8 million for the first three months of 2026, compared to €13.8 million for the first three months of 2025, and related to the supply of Jyseleca® to Alfasigma under the transition agreement. The related revenues are reported in total net revenues. R&D expenses amounted to €31.0 million for the first three months of 2026, compared to €182.7 million for the first three months of 2025. In the first three months of 2025, the Company recorded increased personnel expenses (mainly related to severance costs), an impairment on fixed assets (related to small molecules programs) and a provision for early termination of collaboration agreements. On top, due to the wind-down of the cell therapy activities the spending in the CAR-T programs decreased in the first three months of 2026 as compared to the first three months of 2025. S&M and G&A expenses amounted to €35.5 million for the first three months of 2026, compared to €43.8 million for the first three months of 2025. This decrease was mainly due to lower personnel costs (primarily severance costs). Other operating income amounted to €1.1 million for the first three months of 2026, compared to €6.6 million for the first three months of 2025, mainly driven by lower grant and R&D incentives income. Net financial income amounted to €77.7 million for the first three months of 2026, compared to net financial income of €2.4 million for the first three months of 2025. Fair value adjustments and net currency exchange results amounted to a positive amount of €64.3 million for the first three months of 2026, compared to a negative amount of €9.4 million for the first three months of 2025, and were primarily attributable to €40.0 million of positive changes in fair value of financial investments and €23.8 million of unrealized currency exchange gains on our cash and cash equivalents and financial investments at amortized cost in U.S. dollars. Net other financial income amounted to €13.4 million for the first three months of 2026, compared to net other financial income of €11.8 million for the first three months of 2025. Net interest income amounted to €12.9 million for the first three months of 2026, compared to €12.0 million of net interest income for the first three months of 2025. Fair value gains and interest income derived from cash, cash equivalents and financial investments excluding any currency exchange results amounted to €24.4 million for the first three months of 2026 (compared to €24.9 million for the same period last year). The Company reported a net profit from continuing operations of €13.9 million for the first three months of 2026, compared to a net loss from its continuing operations of €154.5 million for the first three months of 2025. Net profit from discontinued operations related to Jyseleca® amounted to €0.6 million for the first three months of 2026, compared to net profit amounting to €1.1 million for the first three months of 2025. Galapagos reported a net profit of €14.5 million for the first three months of 2026, compared to a net loss of €153.4 million for the first three months of 2025. Cash position Financial investments and cash and cash equivalents totaled €2,982.2 million on March 31, 2026, as compared to €2,998.0 million on December 31, 2025. The cash and cash equivalents and financial investments included $2,546.4 million held in U.S. dollars ($2,159.0 million on December 31, 2025) which could generate foreign exchange gains or losses in the financial results in accordance with the fluctuation of the EUR/U.S. dollar exchange rate as the Company’s functional currency is EUR (translated at a rate of 1.1498 €/$ at March 31, 2026). Total net decrease in cash and cash equivalents and financial investments amounted to €15.8 million during the first three months of 2026, compared to a net decrease of €20.5 million during the first three months of 2025. This net decrease was composed of (i) €77.9 million of operational cash burn 3 , which includes cash in of €16.1 million related to the return on financial investments, (ii) €60.8 million of positive exchange rate differences, positive changes in fair value of current financial investments, variation in accrued interest income, (iii) €1.0 million acquisition of equity investments, and (iv) €2.3 million of net cash in related to the sale of subsidiaries. Conference call and webcast presentation Galapagos will host a conference call on May 7, 2026, at 14:00 CET / 08:00 AM ET. To participate, please register using this link . Dial-in details will be provided upon registration. Participants can join the call 10 minutes before the start time using the access information received by email or via the “call me” feature. The live call and presentation will be available on www. glpg.com or via the following link . A replay and related materials will be available shortly after the call in the investors section of the website. About Galapagos Galapagos (to be renamed Lakefront Biotherapeutics as of May 8, 2026) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Galapagos prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit or follow us on LinkedIn or X . For further information, contact Galapagos: Investor Relations Sherri Spear +1 412 522 6418 sherri.spear@glpg.com Forward-looking statements This press release contains forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,’ “explore,” “further” as well as similar expressions. These statements include, but are not limited to, the guidance from management regarding our financial results and statements on cash position (including guidance regarding the expected results and operational use of cash for the fiscal year 2026 and statements regarding foreign exchange gains or losses in accordance with the fluctuations of the EUR/U.S. dollar exchange rate); statements regarding our business development strategy, including statements regarding our name change to Lakefront Biotherapeutics and our potential partnering or acquisition opportunities, including with the collaboration arrangements between us and Gilead, and the final terms and expected benefits of such opportunities and collaboration; statements regarding the proposed acquisition by Gilead of Ouro and our proposed collaboration with Gilead on Ouro’s portfolio; statements relating to the expected benefits and potential of gamgertamig and BCMA targeted T cell engagers; statements regarding the potential attributes and benefits of our product candidates and partnered and licensed programs, statements regarding our investments in other companies, including Coultreon and the clinical development of its product candidate COL-5671, and any of our future product candidates or approved products, if any, including statements regarding the expected timing, design and readouts of our ongoing and planned preclinical studies and clinical trials, including but not limited to GLPG3667 in SLE and DM, including recruitment for trials and interim or topline results for trials and studies in our portfolio, statements regarding the potential attributes and benefits of our product candidates, statements regarding our commercialization efforts for our product candidates and any of our future approved products, if any; statements regarding the wind down of our cell therapy activities, including statements regarding the expected costs and benefits of such wind down, the anticipated reduction in work force and related site closures, and the expected timeline for completing such wind down. Galapagos cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, the risk that our expectations and management’s guidance regarding our 2026 operating expenses, cash position and other financial estimates may be incorrect (including because one or more of its assumptions underlying our revenue or expense expectations may not be realized); the risks associated with the changes to our capital allocation strategies; the risk that the potential acquisition by Gilead of Ouro Medicines is not consummated in the expected timing and terms, or at all; the risk that our collaboration with Gilead is not consummated in the expected timing or at all (including as a result of our related party procedures and our ability to satisfy legal and regulatory requirements), or if consummated, the risk that we are not able to realize the benefits of such collaboration; the risk that final terms of such collaboration materially deviate from those described in this press release; the risk that we will not be able to execute on our currently contemplated business plan or strategy and/or will revise our business plan or strategy; risks related to our ability to successfully identify, pursue and consummate new transformational business development transactions, including our ability to identify product candidates that will have commercial success and/or be profitable; risks related to our ability to satisfy legal and regulatory requirements (including antitrust requirements related to both us and Gilead), amend our existing agreement with Gilead, and address other factors outside our control that may impact our ability to consummate any potential transaction timely or at all, or if consummated, to realize the benefits of such transaction; the risks related to our ability to successfully implement the wind down of our cell therapy activities within the expected timeframe or at all, or if implemented, will achieve its anticipated economic benefits; risks related to negative impacts of the wind down (whether or not completed) on our stock price, employee retention, business relationships and business generally (including risk of litigation); risks associated with Galapagos’ product candidates and partnered and licensed programs; the risk that ongoing and future clinical trials may not be completed in the currently envisaged timelines or at all; the inherent risks and uncertainties associated with competitive developments, clinical trials, recruitment of patients, product development activities and regulatory approval requirements (including the possibility of unfavorable new clinical data and further analyses of existing clinical data, the risks related to clinical failure at any stage of clinical development; uncertainty inherent to patient enrollment and enrollment rate, our ability to use and expand our drug discovery efforts, competition, side effects caused by our product candidates, delays in obtaining regulatory approval of manufacturing processes and facilities or disruptions in manufacturing processes, and the rate and degree of market acceptance of our products, if approved), the possibility of differing perspectives and requirements by local regulatory authorities, and new or changing government regulations; risks related to the commercialization of our products, if approved; risks related to our ability to implement our business model, strategic plans for our business, product candidates and technology; risks related to the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; risks related to our ability to enter into strategic arrangements and strategic collaboration agreements; risks related to our ability to maintain and establish collaborations; risks related to our ability to attract and retain qualified employees and key personnel); risks related to our reliance on collaborations with third parties (including, but not limited to, our collaboration partner Gilead); the risk that our estimates regarding the commercial potential of our product candidates (if approved) or expectations regarding the costs and revenues associated with the commercialization rights may be inaccurate; and risks related to geopolitical conflicts and macro-economic events. A further list and description of these risks, uncertainties and other risks can be found in our filings and reports with the Securities and Exchange Commission (SEC), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the results of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation. i General and administrative ii Sales and marketing iii The operational cash burn (or operational cash flow if this liquidity measure is positive) is equal to the increase or decrease in the cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus: • the net proceeds, if any, from share capital and share premium increases included in the net cash flows generated from/used in (-) financing activities • the net proceeds or cash used, if any, related to the acquisitions or disposals of businesses; the acquisition of financial assets held at fair value through other comprehensive income; the movement in restricted cash and movement in financial investments, if any, the cash advances and loans given to third parties, if any, included in the net cash flows generated from/used in (-) investing activities • the cash used for other liabilities related to the acquisition or disposal of businesses, if any, included in the net cash flows generated from/used in (-) operating activities. This alternative liquidity measure is in the view of the Company an important metric for a biotech company in the development stage. The operational cash burn for the first three months of 2026, amounted to €77.9 million and can be reconciled to the cash flow statement by considering the decrease in cash and cash equivalents of €21.8 million, adjusted by (i) the net sale of financial investments amounting to €54.8 million, (ii) the cash-in related to the sale of subsidiaries of €2.3 million, and (iii) the acquisition of equity investments of €1.0 million. Addendum Consolidated statements of income and comprehensive income/loss (-) (unaudited) Consolidated income statement Three months ended March 31 (thousands of €, except per share data) 2026 2025 Supply revenues 4,905 13,780 Collaboration revenues 1,576 61,197 Total net revenues 6,481 74,977 Cost of sales (4,799) (13,729) Research and development expenses (30,962) (182,752) Sales and marketing expenses (2,770) (4,174) General and administrative expenses (32,735) (39,623) Other operating income 1,082 6,593 Operating loss (63,703) (158,708) Fair value adjustments and net currency exchange differences 64,241 (9,443) Other financial income 13,555 12,564 Other financial expenses (137) (780) Profit/loss (-) before tax 13,956 (156,367) Income taxes (70) 1,814 Net profit/loss (-) from continuing operations 13,886 (154,553) Net profit from discontinued operations, net of tax 606 1,150 Net profit/loss (-) 14,492 (153,403) Net profit/loss (-) attributable to: Owners of the parent 14,492 (153,403) Basic and diluted earnings/loss (-) per share 0.22 (2.33) Basic and diluted earnings/loss (-) per share from continuing operations 0.21 (2.35) Consolidated statement of comprehensive income/loss (–) Three months ended March 31 (thousands of €) 2026 2025 Net profit/loss (-) 14,492 (153,403) Items that will not be reclassified subsequently to profit or loss: Fair value adjustment financial assets held at fair value through other comprehensive income 9 (2,005) Items that may be reclassified subsequently to profit or loss: Translation differences, arisen from translating foreign activities (262) (533) Other comprehensive loss, net of income tax (253) (2,538) Total comprehensive income/loss (-) attributable to: Owners of the parent 14,239 (155,941) Total comprehensive income/loss (-) attributable to owners of the parent arises from: Continuing operations 13,633 (157,091) Discontinued operations 606 1,150 Total comprehensive income/loss (-), net of income tax 14,239 (155,941) Consolidated statements of financial position (unaudited) (thousands of €) March 31, 2026 December 31, 2025 Assets Intangible assets other than goodwill 746 848 Property, plant and equipment 76,950 80,663 Deferred tax assets 163 195 Non-current R&D incentives receivables 114,575 126,662 Non-current contingent consideration receivable 46,796 47,750 Equity investments 47,933 46,809 Other non-current assets 2,954 2,959 Convertible loan 21,575 21,175 Non-current assets 311,692 327,061 Inventories 17,693 22,493 Trade and other receivables 21,738 20,706 Current R&D incentives receivables 32,296 31,208 Current financial investments 2,915,435 2,910,180 Cash and cash equivalents 66,805 87,868 Other current assets 4,075 7,002 Current assets from continuing operations 3,058,042 3,079,457 Assets in disposal group classified as held for sale 2,695 - Total current assets 3,060,737 3,079,457 Total assets 3,372,429 3,406,518 Equity and liabilities Share capital 293,937 293,937 Share premium account 2,736,994 2,736,994 Other reserves (8,628) (8,637) Translation differences 2,735 2,997 Accumulated result 228,331 210,577 Total equity 3,253,369 3,235,868 Non-current lease liabilities 4,851 5,186 Other non-current liabilities 13,785 12,601 Non-current liabilities 18,636 17,787 Current lease liabilities 1,584 1,729 Trade and other liabilities 95,766 104,647 Provisions 2,130 45,499 Current tax payable 912 956 Current deferred income 32 32 Current liabilities 100,424 152,863 Total liabilities 119,060 170,650 Total equity and liabilities 3,372,429 3,406,518 Consolidated cash flow statements (unaudited) Three months ended March 31 (thousands of €) 2026 2025 Net profit/loss (-) of the period 14,492 (153,403) Decrease in provisions (43,371) - Adjustment for non-cash transactions (57,849) 81,056 Adjustment for items to disclose separately under operating cash flow (12,268) (13,796) Adjustment for items to disclose under investing and financing cash flows (3,546) (9,105) Change in working capital other than deferred income 7,930 111,624 Decrease in deferred income - (59,364) Cash used in operations (94,612) (42,988) Interest paid (64) (208) Interest received 12,012 4,813 Corporate taxes paid (86) (224) Net cash flows used in operating activities (82,750) (38,607) Purchase of property, plant and equipment (123) (5,095) Purchase of intangible fixed assets - (155) Proceeds from disposal of property, plant and equipment 1,317 - Purchase of financial investments (50,145) (340,000) Investment income received related to financial investments 4,136 7,768 Sale of financial investments 105,000 391,802 Convertible loan issued to third party - (1,500) Cash in from the disposal of subsidiaries, net of cash disposed of 2,343 31,925 Acquisition of equity investments held at fair value through other comprehensive income (1,031) - Net cash flows generated from investing activities 61,497 84,745 Payment of lease liabilities (510) (1,011) Net cash flows used in financing activities (510) (1,011) Increase/decrease (-) in cash and cash equivalents (21,763) 45,127 Cash and cash equivalents at beginning of the period 87,868 64,239 Increase/decrease (-) in cash and cash equivalents (21,763) 45,127 Effect of exchange rate differences on cash and cash equivalents 700 (1,299) Cash and cash equivalents at end of the period 66,805 108,067 Consolidated statements of changes in equity (unaudited) (thousands of €) Share capital Share premium account Translation differences Other reserves Accumulated result Total On January 1, 2025 293,937 2,736,994 3,472 (3,158) (134,306) 2,896,939 Net loss (153,403) (153,403) Other comprehensive loss (533) (2,005) (2,538) Total comprehensive loss (533) (2,005) (153,403) (155,941) Share-based compensation 6,896 6,896 On March 31, 2025 293,937 2,736,994 2,939 (5,163) (280,813) 2,747,894 On January 1, 2026 293,937 2,736,994 2,997 (8,637) 210,577 3,235,868 Net profit 14,492 14,492 Other comprehensive income/loss (-) (262) 9 (253) Total comprehensive income/loss (-) (262) 9 14,492 14,239 Share-based compensation 3,262 3,262 On March 31, 2026 293,937 2,736,994 2,735 (8,628) 228,331 3,253,369 Attachment Attachment Galapagos First Quarter Earnings 2026 PR - FINAL CLEAN

Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.4 billion FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2026. “Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance," said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Building on the strongest pipeline in Gilead’s history, we are adding potentially best-in-disease assets and platforms in oncology and inflammation from our acquisitions of Arcellx, Ouro Medicines and Tubulis. With up to four potential launches and five Phase 3 updates anticipated in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by lower sales of Veklury® (remdesivir), as well as chronic hepatitis C virus (“HCV”) and Cell Therapy products. Diluted earnings per share (“EPS”) was $1.61 in the first quarter 2026 compared to $1.04 in the same period in 2025. The increase was primarily driven by net unrealized gains from equity securities compared to net unrealized losses in 2025 and higher product sales, as well as lower acquired in-process research and development (“IPR&D”) expenses. The increase was partially offset by higher income tax and selling, general and administrative (“SG&A”) expenses. Non-GAAP diluted EPS was $2.03 in the first quarter 2026 compared to $1.81 in the same period in 2025. The increase was primarily driven by higher product sales and lower acquired IPR&D expenses, partially offset by higher income tax and SG&A expenses. As of March 31, 2026, Gilead had $8.6 billion of cash, cash equivalents and marketable debt securities compared to $10.6 billion as of December 31, 2025. The decrease was primarily driven by $2.8 billion of debt repayments, $1.0 billion of dividend payments and $419 million of common stock repurchases, partially offset by $2.5 billion of operating cash flow. First Quarter 2026 Product Sales Total first quarter 2026 product sales increased 5% to $6.9 billion compared to the same period in 2025. Total first quarter 2026 product sales excluding Veklury increased 8% to $6.8 billion compared to the same period in 2025, primarily due to higher sales of HIV products, Trodelvy and Livdelzi, partially offset by lower sales of HCV and Cell Therapy products. HIV product sales increased 10% to $5.0 billion in the first quarter 2026 compared to the same period in 2025, primarily driven by higher demand and average realized price, partially offset by unfavorable inventory dynamics. Biktarvy®(bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 7% to $3.4 billion in the first quarter 2026 compared to the same period in 2025, primarily driven by higher demand and average realized price, partially offset by unfavorable inventory dynamics. Descovy®(FTC 200mg/TAF 25mg) sales increased 38% to $807 million in the first quarter 2026 compared to the same period in 2025, primarily driven by higher average realized price and demand. The Liver Disease portfolio sales increased 1% to $767 million in the first quarter 2026 compared to the same period in 2025, primarily reflecting higher demand for Livdelzi, partially offset by unfavorable inventory dynamics and lower sales for HCV products. Veklury sales decreased 52% to $144 millionin the first quarter 2026 compared to the same period in 2025, primarily driven by lower rates of COVID-19-related hospitalizations. Cell Therapy product sales decreased 12% to $407 million in the first quarter 2026 compared to the same period in 2025, reflecting ongoing competitive headwinds. Yescarta® (axicabtagene ciloleucel) sales decreased 14% to $332 million in the first quarter 2026 compared to the same period in 2025, primarily driven by in- and out-of-class competition. Tecartus® (brexucabtagene autoleucel) sales decreased 4% to $75 million in the first quarter 2026 compared to the same period in 2025, primarily driven by in-class competition. Trodelvy® (sacituzumab govitecan-hziy) sales increased 37% to $402 million in the first quarter 2026 compared to the same period in 2025, primarily driven by higher demand, favorable inventory dynamics and higher average realized price. First Quarter 2026 Product Gross Margin, Operating Expenses and Effective Tax Rate Product gross margin was 79.2% in the first quarter 2026 compared to 76.7% in the same period in 2025. Non-GAAP product gross margin was 87.5% in the first quarter 2026 compared to 85.5% in the same period in 2025. These increases are primarily due to the expiration of a royalty-related obligation and product mix. Research and development (“R&D”) expenses remained relatively flat at $1.4 billion in the first quarter 2026 compared to the same period in 2025, primarily due to lower oncology clinical study activity and lower restructuring costs being fully offset by higher investment in virology clinical manufacturing. Non-GAAP R&D expenses were $1.4 billion in the first quarter 2026 compared to $1.3 billion in the same period in 2025, primarily driven by higher investment in virology clinical manufacturing, partially offset by lower oncology clinical study activity. Acquired IPR&D expenses were $107 million in the first quarter 2026, primarily related to an $80 million upfront payment related to our collaboration with Suzhou Genhouse Bio Co., Ltd. (“Genhouse”). SG&A expenses were $1.5 billion in the first quarter 2026 compared to $1.3 billion in the same period in 2025, primarily driven by higher HIV promotional expenses and donations of equity securities made to the Gilead Foundation. Non-GAAP SG&A expenses were $1.4 billion in the first quarter 2026 compared to $1.2 billion in the same period in 2025, primarily due to higher HIV promotional expenses. The effective tax rate (“ETR”) was 21.7% in the first quarter 2026 compared to 20.2% in the same period in 2025. The non-GAAP ETR was 18.3% in the first quarter 2026 compared to 16.3% in the same period in 2025. These increases are primarily driven by a prior year state tax benefit that did not recur. Guidance and Outlook For the full year 2026, Gilead now expects: (in millions, except per share amounts) May 7, 2026 Guidance Comparison to February 10, 2026 Guidance Low End High End Product sales $ 30,000 $ 30,400 Previously $29,600 to $30,000 Product sales excluding Veklury $ 29,400 $ 29,800 Previously $29,000 to $29,400 Veklury $ 600 $ 600 Unchanged Diluted (loss) earnings per share $ (3.25 ) $ (2.85 ) Previously $6.75 to $7.15 Non-GAAP diluted (loss) earnings per share $ (1.05 ) $ (0.65 ) Previously $8.45 to $8.85 As compared to our February guidance, our updated full year 2026 GAAP and non-GAAP diluted earnings per share guidance was reduced by approximately $9.50 due to the anticipated acquired IPR&D charges of $11.5 billion as well as financing costs related to the Arcellx, Inc. (“Arcellx”), Ouro Medicines, LLC (“Ouro”), and Tubulis GmbH (“Tubulis”) transactions discussed further below. Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2026 guidance is provided in the accompanying tables. The financial guidance is subject to a number of risks and uncertainties. See the Forward-Looking Statements section below. Key Updates Since Our Last Quarterly Release Virology Announced U.S. Food and Drug Administration (“FDA”) accepted New Drug Application for bictegravir and lenacapavir (“BIC/LEN”) for virologically suppressed people with HIV under priority review, with a Prescription Drug User Fee Act (“PDUFA”) target action date of August 27, 2026. Presented late-breaking Phase 3 results from the ARTISTRY-1 and ARTISTRY-2 trials at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI), evaluating the investigational daily oral single-tablet regimen of BIC/LEN for virologically suppressed people with HIV. BIC/LEN maintained high levels of virologic suppression, demonstrating comparable efficacy to complex regimens and to Biktarvy at Week 48 in people with HIV who switched antiretroviral therapy. These data support global regulatory filings. Announced a $12 million investment to the Community Health Worker Comprehensive HIV Prevention Initiative program to expand HIV prevention initiatives across 14 U.S. states and the District of Columbia. Announced a new investment from the U.S. State Department, the U.S. President’s Emergency Plan for AIDS Relief (“PEPFAR”) and The Global Fund to deliver lenacapavir for HIV prevention to an additional 1 million people, bringing the total commitment up to 3 million people in countries supported by both PEPFAR and the Global Fund. Oncology Completed the acquisition of Arcellx for $115 per share, or an implied equity value of $7.8 billion, and one contingent value right of $5 per share. This acquisition builds on an existing collaboration agreement with Arcellx for the development of anitocabtagene autoleucel (“anito-cel”) in relapsed or refractory (“R/R”) multiple myeloma (“MM”), and also adds Arcellx’s D-Domain BCMA binder that has the potential to strengthen Gilead’s portfolio in oncology and inflammation. Announced that the Biologics License Application for anito-cel in 4L+ R/R MM has been accepted by FDA, with a PDUFA target action date of December 23, 2026. Announced a definitive agreement to acquire Tubulis, a private clinical-stage biotechnology company developing next-generation antibody-drug conjugates (“ADC”), including lead asset TUB-040, a NaPi2b-directed topoisomerase-I inhibitor ADC currently in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer. Closing of the transaction is subject to expiration or termination of certain regulatory filings and other customary conditions. Received FDA full approval for Tecartus in adult patients with R/R mantle cell lymphoma, following an accelerated approval in this setting in July 2020. Tecartus’ label now includes efficacy, safety and pharmacokinetic data from Cohort 3 of the ZUMA-2 study in patients who are R/R after one or more lines of therapy and who are Bruton tyrosine kinase inhibitor-naïve. Inflammation Announced a definitive agreement to acquire Ouro, a private clinical-stage biotechnology company developing T cell engager (“TCE”) therapies for autoimmune diseases. This acquisition adds Ouro’s lead asset, OM336 (gamgertamig), a BCMAxCD3 TCE, to Gilead’s portfolio. Closing of the transaction is subject to expiration or termination of certain regulatory filings and other customary conditions. Gilead has entered into a framework agreement with Galapagos NV (“Galapagos”) in relation to this acquisition, which includes equally splitting the $1.675 billion upfront payment and up to $500 million in milestone payments, among other terms. Corporate The Board declared a quarterly dividend of $0.82 per share of common stock for the second quarter of 2026. The dividend is payable on June 29, 2026, to stockholders of record at the close of business on June 15, 2026. Future dividends will be subject to Board approval. Certain amounts and percentages in this press release may not sum or recalculate due to rounding. Conference Call At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead’s results. A live webcast will be available on http://investors.gilead.com and will be archived on www.gilead.com for one year. Non-GAAP Financial Information The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets and other items that are considered unusual or not representative of underlying trends of Gilead’s business, fair value adjustments of equity securities, the related tax charges or benefits associated with such exclusions and other discrete tax charges or benefits not representative of underlying trends such as changes in tax laws, transfers of intangible assets between certain legal entities, and effects of legal entity restructurings. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation.Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Forward-Looking Statements Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead’s ability to achieve its full year 2026 financial guidance, including as a result of the uncertainty of the amount and timing of Veklury revenues, the impact from Medicare Part D pricing reform in the Inflation Reduction Act, the expiration of subsidies related to the Affordable Care Act, our most-favored-nation pricing agreement with the U.S. government, changes in U.S. regulatory or legislative policies, and changes in U.S. trade policies, including tariffs; Gilead’s ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology, oncology, inflammation and other programs; Gilead’s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the arrangements with Arcellx, Galapagos, Genhouse, Ouro, PEPFAR, The Global Fund, and Tubulis; the possibility that various closing conditions for any proposed acquisitions, collaborations or licensing arrangements may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of any such transaction; the risk that Gilead’s U.S. manufacturing and R&D investment may not achieve their intended benefits; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Tecartus, bictegravir, and lenacapavir, (such as ARTISTRY-1, ARTISTRY-2, and ZUMA-2), and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to resolve the issues cited by the FDA in pending clinical holds to the satisfaction of the FDA and the risk that FDA may not remove such clinical holds, in whole or in part, in a timely manner or at all; Gilead’s ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead’s ability to receive or maintain regulatory approvals in a timely manner or at all, and the risk that any such approvals, if granted, may be subject to significant limitations on use and may be subject to withdrawal or other adverse actions by the applicable regulatory authority, including those involving BIC/LEN and anito-cel; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of Gilead’s products over other therapies and may therefore be reluctant to prescribe the products, including Tecartus; Gilead’s ability to effectively manage the access strategy relating to lenacapavir for HIV PrEP, subject to necessary regulatory approvals; and other risks identified from time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended March 31, 2026 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements. Additional information is available on our Investor Relations website, https://investors.gilead.com. Among other things, an estimate of Acquired IPR&D expenses is expected to be made available on the Quarterly Results page within the first ten (10) days after the end of each quarter. # # # Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITE®, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, HEPSERA®, JYSELECA®, LIVDELZI®/LYVDELZI®, LETAIRIS®, ODEFSEY®, SOVALDI®, STRIBILD®, SUNLENCA®, TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA®, YEZTUGO®/YEYTUO® and ZYDELIG®. Other trademarks and trade names are the property of their respective owners. For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235). GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Three Months Ended March 31, (in millions, except per share amounts) 2026 2025 Revenues: Product sales $ 6,946 $ 6,613 Royalty, contract and other revenues 14 54 Total revenues 6,960 6,667 Costs and expenses: Cost of goods sold 1,445 1,540 Research and development expenses 1,372 1,379 Acquired in-process research and development expenses 107 253 Selling, general and administrative expenses 1,451 1,258 Total costs and expenses 4,374 4,430 Operating income 2,586 2,237 Interest expense 240 260 Other (income) expense, net (235 ) 328 Income before income taxes 2,580 1,649 Income tax expense 559 334 Net income $ 2,021 $ 1,315 Basic earnings per share $ 1.63 $ 1.06 Diluted earnings per share $ 1.61 $ 1.04 Shares used in basic earnings per share calculation 1,242 1,246 Shares used in diluted earnings per share calculation 1,254 1,259 Supplemental Information: Cash dividends declared per share $ 0.82 $ 0.79 Product gross margin 79.2 % 76.7 % Research and development expenses as a % of revenues 19.7 % 20.7 % Selling, general and administrative expenses as a % of revenues 20.9 % 18.9 % Operating margin 37.2 % 33.6 % Effective tax rate 21.7 % 20.2 % GILEAD SCIENCES, INC. TOTAL REVENUE SUMMARY (unaudited) Three Months Ended March 31, (in millions, except percentages) 2026 2025 Change Product sales: HIV $ 5,030 $ 4,587 10 % Liver Disease 767 758 1 % Oncology 810 757 7 % Other 196 209 (6 )% Total product sales excluding Veklury 6,802 6,311 8 % Veklury 144 302 (52 )% Total product sales 6,946 6,613 5 % Royalty, contract and other revenues 14 54 (75 )% Total revenues $ 6,960 $ 6,667 4 % GILEAD SCIENCES, INC. NON-GAAP FINANCIAL INFORMATION(1) (unaudited) Three Months Ended March 31, (in millions, except percentages) 2026 2025 Change Non-GAAP: Cost of goods sold $ 869 $ 961 (10 )% Research and development expenses $ 1,355 $ 1,338 1 % Acquired IPR&D expenses $ 107 $ 253 (58 )% Selling, general and administrative expenses $ 1,363 $ 1,222 12 % Other (income) expense, net $ (92 ) $ (98 ) (6 )% Diluted earnings per share $ 2.03 $ 1.81 12 % Shares used in non-GAAP diluted earnings per share calculation 1,254 1,259 — % Product gross margin 87.5 % 85.5 % 202 bps Research and development expenses as a % of revenues 19.5 % 20.1 % -61 bps Selling, general and administrative expenses as a % of revenues 19.6 % 18.3 % 126 bps Operating margin 46.9 % 43.4 % 356 bps Effective tax rate 18.3 % 16.3 % 195 bps ________________________________ (1) Refer to Non-GAAP Financial Information section above for further disclosures on non-GAAP financial measures. A reconciliation between GAAP and non-GAAP financial information is provided in the tables below. GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited) Three Months Ended March 31, (in millions, except percentages and per share amounts) 2026 2025 Cost of goods sold reconciliation: GAAP cost of goods sold $ 1,445 $ 1,540 Acquisition-related – amortization(1) (576 ) (579 ) Restructuring (1 ) — Non-GAAP cost of goods sold $ 869 $ 961 Product gross margin reconciliation: GAAP product gross margin 79.2 % 76.7 % Acquisition-related – amortization(1) 8.3 % 8.8 % Restructuring — % — % Non-GAAP product gross margin 87.5 % 85.5 % Research and development expenses reconciliation: GAAP research and development expenses $ 1,372 $ 1,379 Acquisition-related – other costs(2) (3 ) (2 ) Restructuring (14 ) (38 ) Non-GAAP research and development expenses $ 1,355 $ 1,338 Selling, general and administrative expenses reconciliation: GAAP selling, general and administrative expenses $ 1,451 $ 1,258 Restructuring (25 ) (36 ) Other(3) (63 ) — Non-GAAP selling, general and administrative expenses $ 1,363 $ 1,222 Operating income reconciliation: GAAP operating income $ 2,586 $ 2,237 Acquisition-related – amortization(1) 576 579 Acquisition-related – other costs(2) 3 2 Restructuring 40 74 Other(3) 63 — Non-GAAP operating income $ 3,267 $ 2,893 Operating margin reconciliation: GAAP operating margin 37.2 % 33.6 % Acquisition-related – amortization(1) 8.3 % 8.7 % Acquisition-related – other costs(2) — % — % Restructuring 0.6 % 1.1 % Other(3) 0.9 % — % Non-GAAP operating margin 46.9 % 43.4 % Other (income) expense, net reconciliation: GAAP other (income) expense, net $ (235 ) $ 328 Gain (loss) from equity securities, net 142 (426 ) Non-GAAP other (income) expense, net $ (92 ) $ (98 ) Income before income taxes reconciliation: GAAP income before income taxes $ 2,580 $ 1,649 Acquisition-related – amortization(1) 576 579 Acquisition-related – other costs(2) 3 2 Restructuring 40 74 (Gain) loss from equity securities, net (142 ) 426 Other(3) 63 — Non-GAAP income before income taxes $ 3,119 $ 2,731 GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued) (unaudited) Three Months Ended March 31, (in millions, except percentages and per share amounts) 2026 2025 Income tax expense reconciliation: GAAP income tax expense $ 559 $ 334 Income tax effect of non-GAAP adjustments: Acquisition-related – amortization(1) 118 120 Acquisition-related – other costs(2) — — Restructuring 6 14 (Gain) loss from equity securities, net (66 ) 20 Discrete and related tax charges(4) (46 ) (42 ) Non-GAAP income tax expense $ 570 $ 446 Effective tax rate reconciliation: GAAP effective tax rate 21.7 % 20.2 % Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments(4) (3.4 )% (3.9 )% Non-GAAP effective tax rate 18.3 % 16.3 % Net income reconciliation: GAAP net income $ 2,021 $ 1,315 Acquisition-related – amortization(1) 458 459 Acquisition-related – other costs(2) 3 2 Restructuring 34 61 (Gain) loss from equity securities, net (77 ) 406 Discrete and related tax charges(4) 46 42 Other(3) 63 — Non-GAAP net (loss) income $ 2,549 $ 2,285 Diluted earnings per share reconciliation: GAAP diluted earnings per share $ 1.61 $ 1.04 Acquisition-related – amortization(1) 0.37 0.36 Acquisition-related – other costs(2) — — Restructuring 0.03 0.05 (Gain) loss from equity securities, net (0.06 ) 0.32 Discrete and related tax charges(4) 0.04 0.03 Other(3) 0.05 — Non-GAAP diluted earnings per share $ 2.03 $ 1.81 Non-GAAP adjustment summary: Cost of goods sold adjustments $ 576 $ 579 Research and development expenses adjustments 17 40 Selling, general and administrative expenses adjustments 88 36 Total non-GAAP adjustments to costs and expenses 681 656 Other (income) expense, net, adjustments (142 ) 426 Total non-GAAP adjustments before income taxes 539 1,082 Income tax effect of non-GAAP adjustments above (58 ) (154 ) Discrete and related tax charges(4) 46 42 Total non-GAAP adjustments to net income $ 528 $ 970 ________________________________ (1) Relates to amortization of acquired intangibles. (2) Adjustments include integration expenses and contingent consideration fair value adjustments associated with Gilead’s recent acquisitions. (3) Adjustments include donations of equity securities to the Gilead Foundation, a California nonprofit organization, during the first quarter of 2026. (4) Represents discrete and related deferred tax charges or benefits primarily associated with transfers of intangible assets from a foreign subsidiary to Ireland and the United States. GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1) (unaudited) (in millions, except percentages and per share amounts) Provided February 10, 2026 Updated May 7, 2026 Projected product gross margin GAAP to non-GAAP reconciliation: GAAP projected product gross margin ~ 79.0% ~ 79.0% Acquisition-related expenses ~ 8.0% ~ 8.0% Non-GAAP projected product gross margin ~ 87.0% ~ 87.0% Projected operating income (loss) GAAP to non-GAAP reconciliation: GAAP projected operating income (loss) $11,400 - $11,900 $(1,000) - $(500) Acquisition-related, restructuring and other expenses ~ 2,400 ~ 3,400 Non-GAAP projected operating income $13,800 - $14,300 $2,400 - $2,900 Projected effective tax rate GAAP to non-GAAP reconciliation:(2) GAAP projected effective tax rate ~ 21% ~ (150%) - (220%) Income tax effect of above non-GAAP adjustments and fair value adjustments of equity securities, and discrete and related tax adjustments (~ 1%) NM Non-GAAP projected effective tax rate ~ 20% ~ 190% - 140% Projected diluted earnings (loss) per share GAAP to non-GAAP reconciliation: GAAP projected diluted earnings (loss) per share $6.75 - $7.15 $(3.25) - $(2.85) Acquisition-related, restructuring and other expenses, fair value adjustments of equity securities and discrete and related tax adjustments ~ 1.70 ~ $2.20 Non-GAAP projected diluted earnings (loss) per share $8.45 - $8.85 $(1.05) - $(0.65) ________________________________ NM - Not Meaningful (1) Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. The non-GAAP full-year guidance includes non-GAAP adjustments to actual current period results as well as adjustments for the known future impact associated with events that have already occurred, such as future amortization of our intangible assets and the future impact of discrete and related deferred tax charges or benefits primarily associated with transfers of intangible assets from a foreign subsidiary to Ireland and the United States. (2) The GAAP and non-GAAP projected effective tax rates for the May 7, 2026 guidance update include the impact of forecasted Acquired IPR&D expenses related to the acquisitions of Arcellx, Ouro and Tubulis, which are not deductible for tax purposes. Without these Acquired IPR&D expenses, the GAAP and non-GAAP projected effective tax rate for FY26 would be ~22% and ~20%, respectively. GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) March 31, December 31, (in millions) 2026 2025 Assets Cash, cash equivalents and marketable debt securities $ 8,625 $ 10,605 Accounts receivable, net 4,741 4,913 Inventories(1) 4,339 4,368 Property, plant and equipment, net 5,638 5,606 Intangible assets, net 16,382 16,978 Goodwill 8,314 8,314 Other assets 8,239 8,239 Total assets $ 56,278 $ 59,023 Liabilities and Stockholders’ Equity Current liabilities $ 9,476 $ 11,813 Long-term liabilities 23,371 24,592 Stockholders’ equity(2) 23,431 22,618 Total liabilities and stockholders’ equity $ 56,278 $ 59,023 ________________________________ (1) Includes current and long-term inventories, which are disclosed separately in the notes to our financial statements in Form 10-K and Form 10-Q. (2) As of March 31, 2026 and December 31, 2025, there were 1,242 and 1,241 shares of common stock issued and outstanding, respectively. GILEAD SCIENCES, INC. SELECTED CASH FLOW INFORMATION (unaudited) Three Months Ended March 31, (in millions) 2026 2025 Net cash provided by operating activities $ 2,544 $ 1,757 Net cash provided by (used in) investing activities 1,770 (415 ) Net cash used in financing activities (4,239 ) (3,426 ) Effect of exchange rate changes on cash and cash equivalents (11 ) 19 Net change in cash and cash equivalents 65 (2,065 ) Cash and cash equivalents at beginning of period 7,564 9,991 Cash and cash equivalents at end of period $ 7,628 $ 7,926 Three Months Ended March 31, (in millions) 2026 2025 Net cash provided by operating activities $ 2,544 $ 1,757 Purchases of property, plant and equipment (117 ) (104 ) Free cash flow(1) $ 2,427 $ 1,653 ________________________________ (1) Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section above. GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited) Three Months Ended March 31, (in millions) 2026 2025 HIV Biktarvy U.S. $ 2,573 $ 2,474 Europe 437 375 Rest of World 352 301 3,361 3,150 Descovy U.S. 761 538 Europe 23 21 Rest of World 23 27 807 586 Genvoya U.S. 215 305 Europe 33 40 Rest of World 16 19 264 364 Odefsey U.S. 153 215 Europe 59 57 Rest of World 9 10 221 281 Symtuza - Revenue share(1) U.S. 107 82 Europe 28 29 Rest of World 3 3 138 114 Yeztugo U.S. 158 — Europe — — Rest of World 7 — 166 — Other HIV(2) U.S. 36 50 Europe 27 31 Rest of World 9 10 73 91 Total HIV U.S. 4,004 3,664 Europe 607 553 Rest of World 419 370 5,030 4,587 GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY - (Continued) (unaudited) Three Months Ended March 31, (in millions) 2026 2025 Liver Disease Livdelzi U.S. 115 40 Europe 18 — Rest of World — — 133 40 Sofosbuvir / Velpatasvir(3) U.S. 141 166 Europe 60 80 Rest of World 82 99 283 346 Vemlidy U.S. 91 100 Europe 13 12 Rest of World 132 140 237 252 Other Liver Disease(4) U.S. 15 28 Europe 78 76 Rest of World 21 17 114 121 Total Liver Disease U.S. 362 335 Europe 170 168 Rest of World 235 256 767 758 Veklury Veklury U.S. 112 199 Europe 14 22 Rest of World 18 82 144 302 Oncology Cell Therapy Tecartus U.S. 30 40 Europe 37 31 Rest of World 8 8 75 78 Yescarta U.S. 120 160 Europe 146 149 Rest of World 67 77 332 386 Total Cell Therapy U.S. 150 200 Europe 183 180 Rest of World 74 84 407 464 Trodelvy Trodelvy U.S. 253 181 Europe 95 75 Rest of World 54 37 402 293 Total Oncology U.S. 403 381 Europe 278 255 Rest of World 129 121 810 757 GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY - (Continued) (unaudited) Three Months Ended March 31, (in millions) 2026 2025 Other AmBisome U.S. 7 5 Europe 59 67 Rest of World 72 66 138 139 Other(5) U.S. 39 47 Europe 8 9 Rest of World 11 14 58 70 Total Other U.S. 46 52 Europe 67 76 Rest of World 83 81 196 209 Total product sales U.S. 4,926 4,631 Europe 1,137 1,073 Rest of World 883 909 $ 6,946 $ 6,613 ________________________________ (1) Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company. (2) Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost. (3) Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”). (4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Sovaldi, Viread and Vosevi. (5) Includes Cayston, Jyseleca, Letairis and Zydelig. Investors: Jacquie Ross, CFA investor_relations@gilead.com Media: Ashleigh Koss public_affairs@gilead.com